Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 914

1.

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Zaman T, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2019 Mar 29;10(25):2475-2483. doi: 10.18632/oncotarget.26810. eCollection 2019 Mar 29.

2.

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.

Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Br J Cancer. 2019 Apr 11. doi: 10.1038/s41416-019-0446-1. [Epub ahead of print]

PMID:
30971774
3.

Genome-wide analysis of common copy number variation and epithelial ovarian cancer risk.

Reid BM, Permuth JB, Chen YA, Fridley BL, Iversen ES, Chen Z, Jim H, Vierkant RA, Cunningham JM, Barnholtz-Sloan JS, Narod S, Risch H, Schildkraut JM, Goode EL, Monteiro AN, Sellers TA.

Cancer Epidemiol Biomarkers Prev. 2019 Apr 4. pii: cebp.0833.2018. doi: 10.1158/1055-9965.EPI-18-0833. [Epub ahead of print]

PMID:
30948450
4.

CHEK2 Alleles Predispose to Renal Cancer in Poland.

Zlowocka-Perlowska E, Narod SA, Cybulski C.

JAMA Oncol. 2019 Feb 28. doi: 10.1001/jamaoncol.2019.0022. [Epub ahead of print] No abstract available.

PMID:
30816943
5.

Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'".

Narod SA.

Hum Genet. 2019 Mar;138(3):291-292. doi: 10.1007/s00439-019-01981-2. Epub 2019 Feb 21.

PMID:
30790050
6.

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2019 Feb 12. doi: 10.1007/s10549-019-05162-7. [Epub ahead of print]

PMID:
30756284
7.

The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.

Giannakeas V, Narod SA.

Cancer. 2019 Feb 12. doi: 10.1002/cncr.32008. [Epub ahead of print] No abstract available.

PMID:
30748004
8.

Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA.

Br J Cancer. 2019 Feb;120(4):398-403. doi: 10.1038/s41416-019-0376-y. Epub 2019 Feb 6.

PMID:
30723304
9.

Computer-Assisted Flagging of Individuals at High Risk of Colorectal Cancer in a Large Health Maintenance Organization Using the ColonFlag Test.

Goshen R, Choman E, Ran A, Muller E, Kariv R, Chodick G, Ash N, Narod S, Shalev V.

JCO Clin Cancer Inform. 2018 Dec;2:1-8. doi: 10.1200/CCI.17.00130.

10.

Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy.

Giannakeas V, Sopik V, Narod SA.

JAMA Netw Open. 2018 Aug 3;1(4):e181100. doi: 10.1001/jamanetworkopen.2018.1100.

11.

Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene MSH6.

Narod S.

JAMA Oncol. 2019 Jan 1;5(1):120. doi: 10.1001/jamaoncol.2018.6908. No abstract available.

PMID:
30629137
12.

Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.

Lubinski J, Huzarski T, Gronwald J, Cybulski C, Debniak T, Sun P, Kim SJ, Kotsopoulos J, Narod SA.

Breast Cancer Res Treat. 2019 Apr;174(3):769-774. doi: 10.1007/s10549-018-05076-w. Epub 2019 Jan 5.

PMID:
30612273
13.

Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.

Kim SJ, Zhang CXW, Demsky R, Armel S, Kim YI, Narod SA, Kotsopoulos J.

Breast Cancer Res Treat. 2019 Apr;174(3):741-748. doi: 10.1007/s10549-018-05118-3. Epub 2019 Jan 2.

PMID:
30603998
14.

Inherited NBN Mutations and Prostate Cancer Risk and Survival.

Rusak B, Kluźniak W, Wokołorczyk D, Stempa K, Kashyap A, Gronwald J, Huzarski T, Dębniak T, Jakubowska A, Masojć B, Akbari MR, Narod SA, Lubiński J, Cybulski C; Polish Hereditary Prostate Cancer Consortium.

Cancer Res Treat. 2018 Dec 13. doi: 10.4143/crt.2018.532. [Epub ahead of print]

15.

The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer.

Garbens A, Wallis CJD, Matta R, Kodama R, Herschorn S, Narod S, Nam RK.

Can Urol Assoc J. 2018 Dec 3. doi: 10.5489/cuaj.5598. [Epub ahead of print]

PMID:
30526806
16.

A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.

Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.

Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.

PMID:
30515680
17.

Prediction of findings at screening colonoscopy using a machine learning algorithm based on complete blood counts (ColonFlag).

Hilsden RJ, Heitman SJ, Mizrahi B, Narod SA, Goshen R.

PLoS One. 2018 Nov 27;13(11):e0207848. doi: 10.1371/journal.pone.0207848. eCollection 2018.

18.

Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy.

Chandrasekar T, Narod SA, Nam RK.

JAMA Oncol. 2018 Nov 1;4(11):1620. doi: 10.1001/jamaoncol.2018.3539. No abstract available.

PMID:
30422247
19.

Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.

Giannakeas V, Cadarette SM, Ban JK, Lipscombe L, Narod SA, Kotsopoulos J.

Br J Cancer. 2018 Nov;119(11):1421-1427. doi: 10.1038/s41416-018-0225-4. Epub 2018 Nov 13.

PMID:
30420611
20.

Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.

Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J.

Gynecol Oncol. 2019 Jan;152(1):145-150. doi: 10.1016/j.ygyno.2018.10.040. Epub 2018 Nov 7.

PMID:
30414741
21.

Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.

Narod SA.

JAMA Oncol. 2018 Dec 1;4(12):1787-1788. doi: 10.1001/jamaoncol.2018.4931. No abstract available.

PMID:
30383137
22.

Personalised medicine and population health: breast and ovarian cancer.

Narod SA.

Hum Genet. 2018 Oct;137(10):769-778. doi: 10.1007/s00439-018-1944-6. Epub 2018 Oct 17. Review.

PMID:
30328515
23.

Predictors of time to death after distant recurrence in breast cancer patients.

Sopik V, Sun P, Narod SA.

Breast Cancer Res Treat. 2019 Jan;173(2):465-474. doi: 10.1007/s10549-018-5002-9. Epub 2018 Oct 16.

PMID:
30328050
24.

Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.

McGrath LJ, Overman RA, Reams D, Cetin K, Liede A, Narod SA, Brookhart MA, Hernandez RK.

Clin Epidemiol. 2018 Sep 26;10:1349-1358. doi: 10.2147/CLEP.S175063. eCollection 2018.

25.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.

Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.

PMID:
30232083
26.

Reply to 'Mutations in RECQL are not associated with breast cancer risk in an Australian population'.

Ahmed H, Lerner-Ellis J, Cybulski C, Metcalfe K, Lubiński J, Narod SA, Akbari MR.

Nat Genet. 2018 Oct;50(10):1348-1349. doi: 10.1038/s41588-018-0233-6. No abstract available.

PMID:
30224648
27.

Time to death in breast cancer patients as an indicator of treatment response.

Narod SA, Giannakeas V, Sopik V.

Breast Cancer Res Treat. 2018 Dec;172(3):659-669. doi: 10.1007/s10549-018-4935-3. Epub 2018 Aug 30.

28.

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.

Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Pelttari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, Lu K, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlow I, Vestrheim Thomsen LC, Bjorge L, Krakstad C, Tangen IL, Kiemeney LA, Aben KKH, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubiński J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A; Ovarian Cancer Association Consortium.

Int J Mol Sci. 2018 Aug 21;19(9). pii: E2473. doi: 10.3390/ijms19092473.

29.

Clinical Cancer Genetics in a Lower-Middle Income Country: Considerations for Policymaking.

Ginsburg O, Narod SA.

J Glob Oncol. 2018 Jul;4:1-3. doi: 10.1200/JGO.18.00081. No abstract available.

30.

RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.

Wallis CJD, Akbari MR, Narod SA, Nam RK.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx105. No abstract available.

PMID:
30053076
31.

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.

Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, Aben KKH, Anton-Culver H, Antonenkova N, Bandera EV, Bean YT, Beckmann MW, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Hogdall CK, Høgdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Jung AY, Karlan BY, Kellar M, Kiemeney LA, Kiong Lim B, Kjaer SK, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lele S, Lester J, Levine DA, Li Z, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LFAG, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Odunsi K, Olson SH, Orlow I, Orsulic S, Paul J, Pejovic T, Pelttari LM, Permuth JB, Pike MC, Poole EM, Rosen B, Rossing MA, Rothstein JH, Runnebaum IB, Rzepecka IK, Schernhammer E, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Thomsen L, Tworoger SS, van Altena AM, Vergote I, Vestrheim Thomsen LC, Vierkant RA, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu AH, Wu X, Xiang YB, Yang H, Zheng W, Ziogas A, Lee AW, Pearce CL, Berchuck A, Schildkraut JM, Ramus SJ, Monteiro ANA, Narod SA, Sellers TA, Gayther SA, Kelemen LE, Chenevix-Trench G, Risch HA, Pharoah PDP, Goode EL, Phelan CM.

PLoS One. 2018 Jul 6;13(7):e0197561. doi: 10.1371/journal.pone.0197561. eCollection 2018.

32.

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.

Jerzak KJ, Cockburn JG, Dhesy-Thind SK, Pond GR, Pritchard KI, Nofech-Mozes S, Sun P, Narod SA, Bane A.

Breast Cancer Res Treat. 2018 Oct;171(3):709-717. doi: 10.1007/s10549-018-4844-5. Epub 2018 Jun 18.

PMID:
29915948
33.

Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2.

Narod S, Sopik V, Cybulski C.

JAMA Oncol. 2018 Jul 1;4(7):1012. doi: 10.1001/jamaoncol.2018.0595. No abstract available.

PMID:
29801022
34.

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.

Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.

PMID:
29793803
35.

Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Gronwald J, Lynch HT, Eisen A, Neuhausen SL, Tung N, Ainsworth P, Weitzel JN, Pal T, Foulkes WD, Eng C, Singer CF, Senter L, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2018 Sep;171(2):421-426. doi: 10.1007/s10549-018-4822-y. Epub 2018 May 17.

PMID:
29774471
36.

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

JAMA Oncol. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211.

37.

The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer.

Sopik V, Narod SA.

Breast Cancer Res Treat. 2018 Aug;170(3):647-656. doi: 10.1007/s10549-018-4796-9. Epub 2018 Apr 24.

38.

Serum osteoprotegerin levels and mammographic density among high-risk women.

Moran O, Zaman T, Eisen A, Demsky R, Blackmore K, Knight JA, Elser C, Ginsburg O, Zbuk K, Yaffe M, Narod SA, Salmena L, Kotsopoulos J.

Cancer Causes Control. 2018 Jun;29(6):507-517. doi: 10.1007/s10552-018-1035-y. Epub 2018 Apr 20.

PMID:
29679262
39.

Genetic testing for young women with breast cancer.

Metcalfe K, Akbari MR, Narod SA.

Lancet Oncol. 2018 Apr;19(4):e182. doi: 10.1016/S1470-2045(18)30162-1. No abstract available.

PMID:
29611519
40.

The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation.

Wallis CJD, Morton G, Herschorn S, Kodama RT, Kulkarni GS, Appu S, Shayegan B, Buckley R, Grabowski A, Narod SA, Nam RK.

Br J Cancer. 2018 May;118(10):1399-1405. doi: 10.1038/s41416-018-0071-4. Epub 2018 Mar 29.

41.

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.

Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W; Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, du Bois A, Harter P, Schwaab I, Karlan BY, Lester J, Orsulic S, Rimel BJ, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MAT, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LCV, Kopperud RK, Bjorge L, Kiemeney LA, Massuger LFAG, Pejovic T, Bruegl A, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Rzepecka IK, Webb PM; Ovarian Cancer Association Consortium.

Br J Cancer. 2018 Apr;118(8):1123-1129. doi: 10.1038/s41416-018-0011-3. Epub 2018 Mar 20.

42.

Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers.

Kim SJ, Huzarski T, Gronwald J, Singer CF, Møller P, Lynch HT, Armel S, Karlan BY, Foulkes WD, Neuhausen SL, Senter L, Eisen A, Eng C, Panchal S, Pal T, Olopade O, Zakalik D, Lubinski J, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.

Int J Epidemiol. 2018 Mar 13. doi: 10.1093/ije/dyy039. [Epub ahead of print]

PMID:
29547931
43.

Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?

Narod SA.

Breast Cancer Res Treat. 2018 Jun;169(3):639-640. doi: 10.1007/s10549-018-4739-5. Epub 2018 Mar 14. No abstract available.

PMID:
29541974
44.

Correction: Serum selenium levels and the risk of progression of laryngeal cancer.

Lubiński J, Marciniak W, Muszynska M, Jaworowska E, Sulikowski M, Jakubowska A, Kaczmarek K, Sukiennicki G, Falco M, Baszuk P, Mojsiewicz M, Kotsopoulos J, Sun P, Narod SA, Lubiński JA.

PLoS One. 2018 Mar 12;13(3):e0194469. doi: 10.1371/journal.pone.0194469. eCollection 2018.

45.

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland.

Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubiński J, Narod SA, Gronwald J.

Hered Cancer Clin Pract. 2018 Feb 27;16:6. doi: 10.1186/s13053-018-0089-x. eCollection 2018.

46.

Is There a Future for Ovarian Cancer Screening?

Narod SA.

JAMA Intern Med. 2018 May 1;178(5):611-612. doi: 10.1001/jamainternmed.2018.0591. No abstract available.

PMID:
29450456
47.

A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis.

Giannakeas V, Sopik V, Narod SA.

Breast Cancer Res Treat. 2018 Jun;169(3):587-594. doi: 10.1007/s10549-018-4716-z. Epub 2018 Feb 14.

PMID:
29445939
48.

Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?

Jacobson M, Narod SA.

Expert Rev Anticancer Ther. 2018 Apr;18(4):305-306. doi: 10.1080/14737140.2018.1438891. Epub 2018 Feb 16. No abstract available.

PMID:
29431530
49.

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, Foulkes WD, Elser C, Cohen SA, Kiechle M, Narod SA, Kotsopoulos J.

Breast Cancer Res Treat. 2018 Jun;169(3):561-571. doi: 10.1007/s10549-018-4694-1. Epub 2018 Feb 5.

PMID:
29404807
50.

Is invasion a necessary step for metastases in breast cancer?

Narod SA, Sopik V.

Breast Cancer Res Treat. 2018 May;169(1):9-23. doi: 10.1007/s10549-017-4644-3. Epub 2018 Jan 20. Review.

Supplemental Content

Support Center